The abstract is read at the publisher; the summary is JClub's.
Peripheral blood TCR repertoire diversity shows a nonlinear decline that accelerates after ~50 years, with the rate further modified by sex and chronic CMV infection in cancer and non-cancer cohorts.
- Why it matters: Immune aging is linked to worse infection and cancer outcomes, but it remains unclear how demographic and chronic viral factors jointly shape TCR diversity loss and whether diversity predicts survival in cancer.
- What they did: The study integrated TCR sequencing from 1.32 billion unique T cell clones across 798 cancer patients and 5052 non-cancer individuals in 14 cohorts, modeling how age, sex, and CMV relate to diversity trajectories.
- The result: In patients with cancer, higher peripheral TCR diversity is associated with improved overall survival across multiple cancer types, even after accounting for age, sex, and CMV effects on diversity.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.